Table 5 Comparison of clinical and demographic characteristics between antifibrotic drug-treated group and non-treated group in JRS stage I with oxygen desaturation on the 6MWT
From: Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis
Non-treated group | Treated group | P value | |
|---|---|---|---|
Age, years | 71.4 ± 6.7 | 71.2 ± 6.9 | 0.91 |
Sex, male/female | 28/9 | 40/8 | 0.42 |
Smoking history, N/F/C | 4/26/7 | 5/31/12 | 0.44 |
GAP staging (I/II/III) | 15/18/4 | 17/26/5 | 0.27 |
PaO2, Torr | 89.1 ± 7.9 | 87.1 ± 7.0 | 0.22 |
%FVC, % | 76.1 ± 19.7 | 70.0 ± 14.4 | 0.10 |
%DLco, % | 58.7 ± 18.0 | 58.0 ± 18.3 | 0.85 |
KL-6, U/ml | 1006 ± 543 | 1181 ± 678 | 0.20 |
SP-D, ng/ml | 319 ± 247 | 331 ± 285 | 0.83 |
6MWD, m | 365 ± 108 | 380 ± 102 | 0.50 |
Lowest SpO2 on 6MWT, % | 86.9 ± 3.1 | 88.2 ± 5.0 | 0.16 |